CompletedPHASE2, PHASE3NCT01506856
Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
Studying Primary peritoneal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gynecologic Oncology Trial & Investigation Consortium
- Principal Investigator
- Keiichi Fujiwara, MD, PhDSaitama Medical University International Medical Center Comprehensive Cancer Center
- Intervention
- Paclitaxel(intravenous) + Carboplatin(intravenous)(drug)
- Enrollment
- 655 enrolled
- Eligibility
- 20 years · FEMALE
- Timeline
- 2010 – 2021
Study locations (30)
- University of Pittsburgh, Pittsburgh, Pennsylvania, United States
- Queen Mary Hospital, Hong Kong, High West, Hong Kong
- Aichi Cancer Center Hospital, Chikusa, Aichi-ken, Japan
- Hirosaki University School of Medicine & Hospital, Hirosaki-shi, Aomori, Japan
- The Jikei University School of Medicine, Kashiwa Hospital, Kashiwa, Chiba, Japan
- NHO Shikoku Cancer Center, Matsuyama, Ehime, Japan
- Ehime University Hospital, Toon-shi, Ehime, Japan
- University of Fukui Hospital, Yoshida, Fukui, Japan
- Gunma University Hospital, Maebashi, Gunma, Japan
- Gunma Prefectural Cancer Center, Ōta, Gunma, Japan
- NHO Kure Medical Center And Chugoku Cancer Center, Kure, Hiroshima, Japan
- Miyoshi Central Hospital, Miyoshi, Hiroshima, Japan
- Hyogo Cancer Center, Akashi, Hyōgo, Japan
- Japanese Red Cross Society Himeji Hospital, Himeji, Hyōgo, Japan
- Kobe City Medical Center General Hospital, Kobe, Hyōgo, Japan
- +15 more locations on ClinicalTrials.gov
Collaborators
Japanese Gynecologic Oncology Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01506856 on ClinicalTrials.govOther trials for Primary peritoneal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07480954Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)Beijing Biotech
- RECRUITINGPHASE1, PHASE2NCT07322094CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian CancerTORL Biotherapeutics, LLC
- RECRUITINGPHASE3NCT06915025Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerImunon
- RECRUITINGPHASE2NCT07023484Personalized Timing of Interval Debulking Surgery in Advanced Ovarian CancerThe University of Hong Kong
- RECRUITINGPHASE2NCT06639074Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT TrialMayo Clinic
- RECRUITINGPHASE1NCT06469281A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersRegeneron Pharmaceuticals
- RECRUITINGPHASE2NCT06492070Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological CancersEmory University
- RECRUITINGPHASE2NCT06434610A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.Shanghai Jiaolian Drug Research and Development Co., Ltd